Five years ago Mark Horowitz seemed an unlikely skeptic of psycho-pharmaceuticals. He had been taking the popular antidepressant Lexapro virtually every day for 15 years. He was so fascinated by the drugs that he spent three years hunched over a dish of human brain cells in a laboratory at King's College London, measuring the effect of human stress hormones and drugs like Prozac and Zoloft.
Then, when he tried to wean himself off the medication, he suffered panic attacks, sleep disruptions and a depression so debilitating that he had to move back to his parents' house in Australia-symptoms that he says were far worse than anything he experienced prior to going on the drugs. He went online and found thousands of others in a similar pickle. They had been unable to kick one of the psychiatric drugs known as Selective Serotonin Reuptake Inhibitors, or SSRIs, which include Lexapro, Zoloft and Prozac, among others. Since withdrawal symptoms were thought to be mild and temporary, many of them, like him, had been told by doctors that they were experiencing a relapse of their depression. The experience galvanized Horowitz to dig deeper into the claims that pharmaceutical companies, and the scientists they fund, have been making about these popular antidepressants.
Hailed as a revolution for the treatment of depression when they first came out in the 1980s, SSRIs have become a mainstay of mental health treatment. Family doctors with little psychiatric training now prescribe them for adults and children alike. In 2019, one in eight Americans-43 million in all-were taking an SSRI, and those numbers have likely risen among a public ridden with COVID-induced anxiety. During the pandemic, doctors phoned in so many new prescriptions for Zoloft, the FDA warned of a drug shortage.
Esta historia es de la edición September 30, 2022 de Newsweek US.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición September 30, 2022 de Newsweek US.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
The Next Phase of War
After thousands of elite soldiers from North Korea joined Vladimir Putin’s forces against Ukraine, how has this latest move affected the conflict?
Saying No to Trump and Men
The election has led some women to boycott relationships and sex
My Fight for Equality and Justice
It will take more than just science to end AIDS. Inclusion, empathy and compassion are essential, too
NEW WORLD ORDER
HOW LEADERS ACROSS THE GLOBE ARE REACTING TO DONALD TRUMP'S REELECTION AS U.S. PRESIDENT
America's Best CONTINUING CARE
EDUCATIONAL OPPORTUNITIES, RESTAURANTstyle dining, unlimited pickleball-an impressive number of amenities are becoming standard at Continuing Care Retirement Communities.
Hey, Don't Be So SAD
Seasonal affective disorder affects millions of people. Here’s how you can prep your body and mind for darker days
Wendi McLendon-Covey
AFTER 10 YEARS OF PLAYING BEVERLY GOLDBERG ON THE GOLDBERGS, Wendi McLendon-Covey was not eager for a break. \"I need to go do a job where I can just throw everything at it and then come home totally exhausted.\"
'I'm the Highest Earner in Esports'
Johan \"NOtail\" Sundstein has won over $7 million but says, \"I don't really crave that status.... I play for my own reasons\"
AMERICA'S BEST Weight Loss CLINICS & CENTERS 2025
WHETHER IT'S FOR MEAL PLANS, PROFESSIONAL guidance or access to medications like GLP-1s, weight loss clinics can offer personalized assistance for those hoping to make sustainable lifestyle changes.
AMERICA'S MOST ANTICIPATED NEW VEHICAL 2025
WHETHER IT'S A NEWLY IMAGined sport utility vehicle or the re-emergence of a highly regarded halo car, the vehicles coming to market in 2025 prove that Americans' attitudes about personal transportation are diverse and are being served from all angles.